Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 17/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334045 | 0.83 | F2 (0.81) | F2MEN1KMT2A | |
| SCHEMBL8550080 | 0.72 | F2 (1.00) | F2 | |
| SCHEMBL8544350 | 0.70 | F2 (0.83) | F2 | |
| SCHEMBL8542916 | 0.69 | F2 (0.76) | F2 | |
| SCHEMBL8545960 | 0.69 | F2 (0.72) | F2 | |
| SCHEMBL8546663 | 0.68 | F2 (0.84) | F2 | |
| SCHEMBL7371793 | 0.68 | F2 (0.86) | F2MEN1KMT2ALMNAMAPT | |
| SCHEMBL8542772 | 0.67 | F2 (0.68) | F2MEN1KMT2ALMNAGAA | |
| SCHEMBL8542767 | 0.67 | F2 (0.74) | F2 | |
| SCHEMBL8546328 | 0.66 | F2 (0.67) | F2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0687253-A1 | NEW 4-AMINOPYRIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME | Roche Diagnostics GmbH (DE) | 1995-12-20 | — | — | EP | disclosed |
| WO-1994020467-A1 | NEW 4-AMINOPYRIDINES, PROCESS FOR PREPARING THE SAME AND MEDICAMENTS CONTAINING THE SAME | BOEHRINGER MANNHEIM GMBH (DE) | 1994-09-15 | — | — | WO | disclosed |